应用超声造影与临床特征预测巨梁状-团块型肝细胞癌及其相关预后
这项前瞻性多中心研究的二次分析纳入三个独立队列共387例接受超声造影和手术切除的肝细胞癌患者,构建了包含早期廓清、低增强成分、肿瘤大小和甲胎蛋白水平的联合预测模型,训练队列AUC为0.89、验证队列AUC为0.81,并对总生存期具有预后价值。
要点
- 早期廓清(60秒前)与巨梁状-团块型肝细胞癌的关联最强,OR为8.82。
- 联合模型训练队列AUC为0.89、验证队列AUC为0.81,阴性预测值分别为94.2%和88.0%。
- 模型对总生存期的风险比为2.26,提示可用于判断预后。
核心结论
- 联合超声造影-临床预测模型可用于识别巨梁状-团块型肝细胞癌亚型并判断预后。
研究设计与样本
- 前瞻性多中心研究(NCT04682886)的二次分析,纳入2017年1月至2022年12月三个独立队列中接受超声造影和手术切除的肝细胞癌患者共387例(平均年龄55.09岁±10.33,342例男性)。
关键影像表现/征象
- 早期廓清(60秒前)与巨梁状-团块型肝细胞癌相关,OR为8.82(95%CI:4.22,18.64),P<.001。
- 低增强成分与巨梁状-团块型肝细胞癌相关,OR为4.03(95%CI:1.78,9.49),P<.001。
- 肿瘤大小与巨梁状-团块型肝细胞癌相关,OR为1.28(95%CI:1.04,1.59),P=.02。
- 血清甲胎蛋白水平大于100 ng/mL与巨梁状-团块型肝细胞癌相关,OR为3.01(95%CI:1.41,6.63),P=.004。
诊断标准与关键数值
- 联合预测模型训练队列AUC为0.89(95%CI:0.85,0.93),验证队列AUC为0.81(95%CI:0.73,0.89)。
- 模型训练队列阴性预测值为94.2%(147/156),验证队列阴性预测值为88.0%(66/75)。
- 模型对总生存期的风险比为2.26(95%CI:1.07,4.79),P=.03。
临床应用与阅片要点
- 两名放射科医师独立审阅超声造影数据并评估阅片者间一致性。
- 早期廓清(60秒前)、低增强成分、肿瘤大小和甲胎蛋白水平大于100 ng/mL被用于构建联合预测模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To develop a combined contrast-enhanced US (CEUS) clinical model for the prediction of macrotrabecular-massive hepatocellular carcinoma (MTM HCC) and evaluate its diagnostic and prognostic values. Materials and Methods This secondary analysis of a prospective multicenter study (ClinicalTrials.gov: NCT04682886) included participants from three independent cohorts who underwent CEUS and surgical resection for HCC between January 2017 and December 2022. Two radiologists independently reviewed CEUS data, and the interreader agreement was evaluated. Logistic regression was performed using the training cohort to determine the predictors associated with MTM HCC, while the validation cohort was used to evaluate the diagnostic and prognostic values of the predictors. Results A total of 387 participants (mean age, 55.09 years ± 10.33 [SD]; 342 male) were included. Four clinical and CEUS features were associated with MTM HCC: early washout (before 60 seconds) (odds ratio [OR]: 8.82 [95% CI: 4.22, 18.64], P < .001), hypoenhancing component (OR: 4.03 [95% CI: 1.78, 9.49], P < .001), tumor size (OR: 1.28 [95% CI: 1.04, 1.59], P = .02), and serum α-fetoprotein level greater than 100 ng/mL (OR: 3.01 [95% CI: 1.41, 6.63], P = .004). The combined predictive model yielded an area under the receiver operating characteristic curve of 0.89 (95% CI: 0.85, 0.93) in the training cohort and 0.81 (95% CI: 0.73, 0.89) in the validation cohort. The model also achieved a negative predictive value of 94.2% (147 of 156) in the training cohort and 88.0% (66 of 75) in the validation cohort, with high prognostic accuracy for overall survival (hazard ratio: 2.26 [95% CI: 1.07, 4.79], P = .03). Conclusion The combined CEUS-clinical predictive model could be used to characterize the MTM HCC subtype and determine prognosis. Keywords: Molecular Imaging-Angiogenesis, Ultrasound-Contrast, Liver, Macrotrabecular-Massive Hepatocellular Carcinoma, Contrast-enhanced US Clinical trial registration no. NCT04682886 Supplemental material is available for this article. © RSNA, 2025.
引用
- Wu J, Liu S, Zhang Y, et al. Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma and Associated Prognosis Using Contrast-enhanced US and Clinical Features. Radiol Imaging Cancer. 2025. PMID: 40607931. doi:10.1148/rycan.240419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。